entity

SMA

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about SMA: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

3Connections
27Hypotheses
1Analyses
0Outgoing
3Incoming
20Experiments
2Debates

No AI portrait yet

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Supplementary Motor Area

cell · 1686 words

SMAD3 — SMAD Family Member 3

gene · 2938 words

SMARCA2 (BRM)

gene · 2683 words

SMAD6 — SMAD Family Member 6

gene · 2543 words

SMAD5 — SMAD Family Member 5

gene · 2466 words

SMAD5 Protein

protein · 2057 words

Outgoing (0)

TargetRelationTypeStr
No outgoing edges

Incoming (3)

SourceRelationTypeStr
29961886is caused bypaper0.90
29614695is caused bypaper0.90
TARDBPassociated_withgene0.60

Targeting Hypotheses (27)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Plasma NfL Elevation Secondary to BBB-Associated Transport D 0.940 - What blood-brain barrier permeability ch
APOE4 Allosteric Rescue via Small Molecule Chaperones 0.765 neurodegeneration APOE4 structural biology and therapeutic
Smartphone-Detected Motor Variability Correction 0.742 neurodegeneration Digital biomarkers and AI-driven early d
TGF-β1–SMAD2/3 Axis as Master Suppressor of Microglial Train 0.712 neuroinflammation What specific astrocyte-derived factors
CSF/Plasma AQP4 Polarization Index as a Novel Biomarker of A 0.705 - What blood-brain barrier permeability ch
Plasma Claudin-5 Proteolytic Fragments Distinguish Paracellu 0.705 - What blood-brain barrier permeability ch
Plasma D-Dimer Elevation Reflects Fibrinogen Leakage and Sec 0.685 - What blood-brain barrier permeability ch
Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mi 0.681 neurodegeneration CRISPR-based therapeutic approaches for
Small Molecule Modulation of Phase Separation 0.640 neurodegeneration What determines the specificity of RNA-p
Blocking Tau Packaging into Small Extracellular Vesicles via 0.610 neuroscience Trans-synaptic tau spreading and propaga
Neurovascular Permeability Score (NVPS): Composite Plasma + 0.600 - Blood-brain barrier permeability changes
APOE4 Structural Correction by Small Molecule Correctors 0.580 neurodegeneration APOE4 targeting in neurodegeneration
Structure-interacting small molecules that stabilize the APO 0.580 neuroscience APOE4-driven lipid metabolism dysregulat
Complement C1q Suppression as Mechanism Linking Exercise Pla 0.560 neurodegeneration What are the specific circulating factor
Small-Molecule FUS Nuclear Import Correctors Rescue Motor Ne 0.550 neurodegeneration Test Hypothesis Fixtures
Plasma NfL Elevation Secondary to BBB-Associated Transport D 0.485 - What blood-brain barrier permeability ch
Plasma TREM2 Ectodomain Glycosylation Pattern as Therapeutic 0.427 biomarkers What biomarkers can reliably detect micr
MT1 Receptor Activation at Low Doses Synchronizes Suprachias 0.405 - What is the minimum effective dose of tr
Small-Molecule Modulation of G3BP1 Condensate Dynamics via P 0.400 neurodegeneration How do disease-associated mutations in G
Dynamic Plasma Exosome-Derived Multi-Analyte Panel Combining 0.389 biomarkers What biomarkers can reliably detect micr
AD fine-mapping identifies causal variants in microglia-spec 0.380 Alzheimer's disease Statistical Fine-Mapping of AD GWAS Loci
TGF-β1-SMAD Signaling Dysregulation 0.380 neurodegeneration Which specific factors in conditioned me
Plasma TREM2 Ectodomain Glycosylation Patterns as Microglial 0.380 biomarkers What biomarkers can reliably detect micr
plasma LPS-binding protein separates causal from compensator 0.346 neurodegeneration How does gut microbiome dysbiosis contri
plasma GFAP separates causal from compensatory states in: Bl 0.346 neurodegeneration Blood-brain barrier permeability changes
Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-00 0.323 molecular neurobiology View
RGS6 isoform switching or small-molecule RGS6 activation as 0.220 neurodegeneration Does RGS6 upregulation or D2 autorecepto

Mentioning Analyses (1)

Scientific analyses that reference this entity

Proteomics Differential Expression in AD CSF and Brain Tissue

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.865

Experiments (20)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
GWAS of plasma NfL in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
GWAS of plasma pTau217 in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
Dairy intake and dementia risk in Malmö Diet and Cancer cohort clinical Alzheimer's disease 0.950 0.00 Swedish community-based adults proposed N/A
GWAS of plasma pTau181 in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
GWAS of plasma GFAP in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
KEEPS Continuation: Long-term effects of menopausal hormone therapy on clinical Alzheimer's disease 0.950 0.00 recently menopausal women with proposed N/A
GWAS of composite biomarker score exploratory Alzheimer's disease 0.900 0.00 human patients - East Asian co proposed N/A
RBG treatment in ApoE-/- atherosclerosis mouse model validation atherosclerosis 0.900 0.00 ApoE-/- mice proposed N/A
APOE4 association with TDP-43 pathology in AD exploratory Alzheimer's disease 0.750 0.00 human patients proposed N/A
s:** - Biochemical binding assays measuring PROTAC selectivity for APO falsification Neurodegeneration 0.400 0.50 cell_line proposed $100,000
Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for P clinical Parkinson's Disease 0.400 0.50 human proposed $5,460,000
Computational Modeling of Alpha-Synuclein Propagation in PD validation Parkinson's Disease 0.400 0.50 human proposed $2,280,000
Alpha-Synuclein Seed Amplification Assay Validation clinical Parkinson's Disease 0.400 0.50 human proposed $7,500,000
Antiviral Therapy Trial for Parkinson's Disease clinical Parkinson's Disease 0.400 0.50 human proposed $5,460,000
Combination Therapy Sequencing in Parkinson's Disease validation Parkinson's Disease 0.400 0.50 human proposed $2,280,000
Genetic Risk Modifiers in DLB Phenotype clinical Neurodegeneration 0.400 0.50 human proposed $7,500,000
DLB Treatment Response Biomarkers — Predicting Cholinesterase Inhibito clinical Neurodegeneration 0.400 0.50 human proposed $6,550,000
Mechanism: Selective Vulnerability of Dopaminergic Neurons in Parkinso validation Parkinson's Disease 0.400 0.50 human proposed $3,000,000
Selective Vulnerability of Dopaminergic Neurons — Mechanism and Protec validation Neurodegeneration 0.400 0.50 cell_line proposed $160,000
Endocannabinoid System Dysfunction Validation in Parkinson's Disease clinical Parkinson's Disease 0.400 0.50 human proposed $6,550,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of [PMID:30335591] Rusmini P, Cortese K, Crippa V, Cristofa Autophagy 2019 2
Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] Litvinchuk A, Suh JH, Guo JL, Lin K, Dav Neuron 2024 1
The cell biology of APOE in the brain. [PMID:37805344] Windham IA, Cohen S Trends Cell Biol 2024 1
The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] Maxine R Nelson, Peng Liu, Ayushi Agrawa Nature neuroscience 2023 1
Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmaco [PMID:34106485] Cacabelos R, Carrera I, Martínez O, Alej Med Res Rev 2021 1
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] Serrano-Pozo A, Das S, Hyman BT Lancet Neurol 2021 1
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] Long JM, Holtzman DM Cell 2019 1
Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation [PMID:31120439] Luo Z, Ahlers-Dannen KE, Spicer MM, Yang JCI Insight 2019 1
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [PMID:31367008] Yamazaki Y, Zhao N, Caulfield TR, Liu CC Nat Rev Neurol 2019 1
Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant [PMID:31873106] Yedlapudi D, Xu L, Luo D, Marsh GB, Todi Sci Rep 2019 1
A systematic review and integrative approach to decode the common molecular link [PMID:28927418] Guin D, Mishra MK, Talwar P, Rawat C, Ku BMC Med Genomics 2017 1
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] Cetindag AC, Schipke CG, Esselmann H, Kr The journal of prevention of A 2026 0
The role of genetic factors in the occurrence of levodopa-induced motor complica [PMID:40632937] ["Radojevi\u0107 B", "Milovanovi\u0107 A Neurological research 2026 0
ASS1 Promotes Atherosclerotic Inflammation Through the NLRP3/IL-33/ST2 Axis in O [PMID:41914296] Wu S, Han F, Qiao Z, Yuan S, Bian X, Zha Frontiers in bioscience (Landm 2026 0
Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] Thedim M, Hu J, Maher M, Wiener-Kronish Br J Anaesth 2026 0
Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] Bae H, Song Z, Ali A, Sasaki T, Tesi N e Geroscience 2026 0
Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401] Stern A, Linial M Geroscience 2026 0
Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsu [PMID:41101204] Sang Y, Cao Y, Li S, Quan Y, Wang S et a Biomaterials 2026 0
Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β path [PMID:41445196] Lin Z, Xiong J, Zhang F, Zhang H, Zhu M Mol Ther 2026 0
Menopause, cognition, and Alzheimer's disease risk. [PMID:41531227] Samudra N, Vemuri M, Weitlauf J Curr Opin Obstet Gynecol 2026 0

Debates (2)

Multi-agent debates referencing this entity

Which proteins are differentially expressed in AD CSF and brain tissue, and do t

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

Is a 12-protein CSF panel superior to existing plasma p-tau217 for clinical AD p

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

Related Research

Hypotheses and analyses mentioning SMA in their description or question text

Plasma Claudin-5 Proteolytic Fragments Distinguish Paracellular BBB Breakdown fr

Score: 0.705 · unknown disease · 2026-04-26

Claudin-5 is the most abundant tight junction protein in brain endothelial cells and is specifically degraded during ear

Plasma D-Dimer Elevation Reflects Fibrinogen Leakage and Secondary Fibrinolysis

Score: 0.685 · unknown disease · 2026-04-26

Plasma fibrinogen leaks across the compromised BBB and undergoes coagulation cascade activation and cross-linking by fac

Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modula

Score: 0.681 · neurodegeneration · 2026-04-04

## Mechanistic Overview Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modulation starts from

Small Molecule Modulation of Phase Separation

Score: 0.640 · neurodegeneration · 2026-04-21

**Molecular Mechanism and Rationale** The therapeutic strategy centers on modulating liquid-liquid phase separation (LL

Blocking Tau Packaging into Small Extracellular Vesicles via ESCRT-III Pathway

Score: 0.610 · neuroscience · 2026-04-22

## Mechanistic Overview Blocking Tau Packaging into Small Extracellular Vesicles via ESCRT-III Pathway starts from the c

Neurovascular Permeability Score (NVPS): Composite Plasma + Imaging Biomarker Pa

Score: 0.600 · unknown disease · 2026-04-26

A LASSO-optimized composite score integrating plasma GFAP, S100B, NFL, soluble PDGFR-β, and claudin-5 fragments to achie

APOE4 Structural Correction by Small Molecule Correctors

Score: 0.580 · neurodegeneration · 2026-04-22

## Mechanistic Overview APOE4 Structural Correction by Small Molecule Correctors starts from the claim that modulating A

Structure-interacting small molecules that stabilize the APOE4 molten globule do

Score: 0.580 · neuroscience · 2026-04-22

## Mechanistic Overview Structure-interacting small molecules that stabilize the APOE4 molten globule domain (Domain III

Complement C1q Suppression as Mechanism Linking Exercise Plasma to PV Interneuro

Score: 0.560 · neurodegeneration · 2026-04-14

## Mechanistic Overview Complement C1q Suppression as Mechanism Linking Exercise Plasma to PV Interneuron Protection sta

Small-Molecule FUS Nuclear Import Correctors Rescue Motor Neuron Toxicity

Score: 0.550 · neurodegeneration · 2026-04-26

ALS-linked FUS mutations (P525L, R521C) impair nuclear import via karyopherin-β2 (Transportin-1), causing cytoplasmic ac

Plasma NfL Elevation Secondary to BBB-Associated Transport Dysfunction Enables L

Score: 0.485 · unknown disease · 2026-04-26

Neurofilament light chain (NfL) is released from damaged neurofilaments into the extracellular space, flowing into CSF a

Plasma TREM2 Ectodomain Glycosylation Pattern as Therapeutic Response Predictor

Score: 0.427 · biomarkers · 2026-04-26

Site-specific glycosylation patterns on circulating TREM2 ectodomain fragments reflect the metabolic state and activatio

MT1 Receptor Activation at Low Doses Synchronizes Suprachiasmatic Nucleus and Re

Score: 0.405 · unknown disease · 2026-04-26

At doses of 25-50 mg, trazodone's metabolite mCPP exhibits partial agonist activity at melatonin MT1 receptors, phase-ad

Small-Molecule Modulation of G3BP1 Condensate Dynamics via PRMT1 Methylation as

Score: 0.400 · neurodegeneration · 2026-04-22

## Mechanistic Overview Small-Molecule Modulation of G3BP1 Condensate Dynamics via PRMT1 Methylation as a Therapeutic St

Dynamic Plasma Exosome-Derived Multi-Analyte Panel Combining YKL-40, sTREM2, and

Score: 0.389 · biomarkers · 2026-04-26

This hypothesis proposes that plasma-derived exosomes carrying YKL-40, sTREM2, and neurogranin provide a superior biomar